SCHEMBL3739121

SCHEMBL3739121

O=C1NCN=C2N=NC=C12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11266465 0.78
SCHEMBL7483306 0.76
SCHEMBL6212505 0.70
SCHEMBL4078808 0.68
SCHEMBL28418210 0.65
SCHEMBL1962941 0.65
SCHEMBL921850 0.64
SCHEMBL8524652 0.63
SCHEMBL16179060 0.61
SCHEMBL1720840 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110337437-B Substituted pyrazolopyrimidinones as PDE2 inhibitors 达特神经科学有限公司 2023-02-03 CN claimed
CN-112513050-A Heterocyclic compounds inhibiting SHP2 activity 大鹏药品工业株式会社 2021-03-16 CN claimed
CN-107406451-B Pyrrolopyrimidines and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors 福马治疗股份有限公司 2019-12-17 CN claimed
EP-3240791-A1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS Forma Therapeutics, Inc. (US) 2017-11-08 EP claimed
WO-2016109515-A1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2016-07-07 WO claimed
US-20160185785-A1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS VALO HEALTH, INC. 2016-06-30 US claimed
EP-2971086-A1 FUNCTIONALIZED 3-ALKYNYL PYRAZOLOPYRIMIDINE ANALOGUES AS UNIVERSAL BASES AND METHODS OF USE ELITechGroup B.V. (NL) 2016-01-20 EP claimed
WO-2014159063-A1 FUNCTIONALIZED 3-ALKYNYL PYRAZOLOPYRIMIDINE ANALOGUES AS UNIVERSAL BASES AND METHODS OF USE ELITECH HOLDING B.V. (NL) 2014-10-02 WO claimed
EP-2689031-A1 FUNCTIONALIZED 3-ALKYNYL PYRAZOLOPYRIMIDINE ANALOGUES AS UNIVERSAL BASES AND METHODS OF USE Elitech Holding B.V. (NL) 2014-01-29 EP claimed
WO-2013048583-A2 DETECTION OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS ELITECH HOLDING B.V. (NL) 2013-04-04 WO claimed
WO-2012129547-A1 FUNCTIONALIZED 3-ALKYNYL PYRAZOLOPYRIMIDINE ANALOGUES AS UNIVERSAL BASES AND METHODS OF USE ELITECH HOLDING B.V. (NL) 2012-09-27 WO claimed
EP-1005471-B1 PYRAZOLO(3,4-D)PYRIMIDINES WITH ANTICONVULSIVE AND ANTIALLERGIC/ANTIASTHMATIC ACTION DRESDEN ARZNEIMITTEL (DE) 2002-09-04 EP claimed
US-20250360137-A1 ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES FREEDOM BIOSCIENCES INC (US) 2025-11-27 US disclosed
EP-4618980-A1 ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES Freedom Biosciences, Inc. (US) 2025-09-24 EP disclosed
EP-4559520-A1 NOVEL AQP4 INHIBITORS Origenis GmbH (DE) 2025-05-28 EP disclosed
US-12018030-B2 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors VALO HEALTH, INC. (US) 2024-06-25 US disclosed
US-6054460-A Anticonvulsive and antiallergic/antiasthmatic pyrazolo-[3,4-d]pyrimidines, and process for preparing ARZNEIMITTELWERK DRESDEN GMBH (DE) 2000-04-25 US disclosed
US-6054460-A Anticonvulsive and antiallergic/antiasthmatic pyrazolo-[3,4-d]pyrimidines, and process for preparing ARZNEIMITTELWERK DRESDEN GMBH (DE) 2000-04-25 US disclosed
WO-1999067243-A1 PYRAZOLO(3,4-D)PYRIMIDINES WITH ANTICONVULSIVE AND ANTIALLERGIC/ANTIASTHMATIC ACTION ARZNEIMITTELWERK DRESDEN GMBH (DE) 1999-12-29 WO disclosed
WO-1999067243-A1 PYRAZOLO(3,4-D)PYRIMIDINES WITH ANTICONVULSIVE AND ANTIALLERGIC/ANTIASTHMATIC ACTION ARZNEIMITTELWERK DRESDEN GMBH (DE) 1999-12-29 WO disclosed